Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. “The Submarine Study”
Eye, Published online: 03 August 2023; doi:10.1038/s41433-023-02676-9Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. “The Submarine Study” (Source: Eye)
Source: Eye - August 3, 2023 Category: Opthalmology Authors: Matias Iglicki Marina Khoury Lucas Donato Diego Jose Quispe Hermino Pablo Negri Javier Ignacio Melamud Source Type: research
Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials
Conclusions
Anti-VEGF therapy is effective and well-tolerated for myopia CNV patients. Anti-VEGF retreatment guided by disease activity criteria can achieve comparable efficacy and potentially reduce anti-VEGF injections.
PROSPERO registration number
CRD42021292806. (Source: BMJ Open)
Source: BMJ Open - July 20, 2023 Category: General Medicine Authors: Dong, L., Li, G., Song, Z., Cheng, X., Bai, J., Zhang, C. Tags: Open access, Ophthalmology Source Type: research
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
CONCLUSION: Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents.PMID:37461836 | DOI:10.1177/11206721231187663 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 18, 2023 Category: Opthalmology Authors: Argyrios Chronopoulos Elisa Huynh Agharza Ashurov James S Schutz Jost B Jonas Lars-Olof Hattenbach Source Type: research
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
CONCLUSION: Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents.PMID:37461836 | DOI:10.1177/11206721231187663 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 18, 2023 Category: Opthalmology Authors: Argyrios Chronopoulos Elisa Huynh Agharza Ashurov James S Schutz Jost B Jonas Lars-Olof Hattenbach Source Type: research
Exudation in Patients with Neovascular Age-Related Macular Degeneration Treated with the Port Delivery System or Monthly Injections
Vascular endothelial growth factor-A (VEGF-A) is a critical stimulus for neovascularization (NV) and excessive vascular leakage resulting in exudation and reduced vision in patients with neovascular age-related macular degeneration (nAMD). 1 Monthly injections of ranibizumab or injections of aflibercept every other month control exudation in most patients and provide substantial improvement in vision.2-4 Observational studies have demonstrated that in clinical practice injection frequency of anti-VEGF agents in patients with nAMD is substantially lower than that in clinical trials and visual outcomes are much worse. (Sourc...
Source: American Journal of Ophthalmology - July 13, 2023 Category: Opthalmology Authors: Anam Akhlaq, David Williams, W. Lloyd Clark, Hannah Khan, Arshad M. Khanani, Lisa Walden, Carl Awh, J. Taylor Graff, Jordan M. Graff, Taku Wakabayashi, Carl Regillo, Katie F. Maass, Natalia Callaway, Shamika Gune, Peter A. Campochiaro Tags: Original Articles Source Type: research
Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy
CONCLUSION: Intravitreal administration of anti-VEGF agents could cause a small but significant greater increase in CCT in PDR than in NPDR eyes in the early period. In patients with DR, no significant difference was found between conbercept and ranibizumab in the early effects on the visual acuity nor in the cornea.PMID:37417939 | DOI:10.1080/15569527.2023.2234036 (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - July 7, 2023 Category: Toxicology Authors: Xuanli Liu Wei Shen Wei Xia Peirong Lu Source Type: research
Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy
CONCLUSION: Intravitreal administration of anti-VEGF agents could cause a small but significant greater increase in CCT in PDR than in NPDR eyes in the early period. In patients with DR, no significant difference was found between conbercept and ranibizumab in the early effects on the visual acuity nor in the cornea.PMID:37417939 | DOI:10.1080/15569527.2023.2234036 (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - July 7, 2023 Category: Toxicology Authors: Xuanli Liu Wei Shen Wei Xia Peirong Lu Source Type: research
Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy
CONCLUSION: Intravitreal administration of anti-VEGF agents could cause a small but significant greater increase in CCT in PDR than in NPDR eyes in the early period. In patients with DR, no significant difference was found between conbercept and ranibizumab in the early effects on the visual acuity nor in the cornea.PMID:37417939 | DOI:10.1080/15569527.2023.2234036 (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - July 7, 2023 Category: Toxicology Authors: Xuanli Liu Wei Shen Wei Xia Peirong Lu Source Type: research
The efficacy of different anti-vascular endothelial growth factor agents, and dexamethasone implant therapy in patients with serous retinal detachment caused by Irvine-Gass syndrome
CONCLUSION: All intravitreal agents were effective in terms of visual results in the SRD patients; however, eyes treated with IVA and IVDI required fewer injections, as compared to the eyes treated with IVB and IVR. Furthermore, SRD entirely resolved in all eyes in the IVA group at the final follow-up visit.PMID:37408434 | DOI:10.1177/11206721231185909 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 6, 2023 Category: Opthalmology Authors: Bu ğra Karasu Enes Kesim Ali R ıza Cenk Celebi Source Type: research
The efficacy of different anti-vascular endothelial growth factor agents, and dexamethasone implant therapy in patients with serous retinal detachment caused by Irvine-Gass syndrome
CONCLUSION: All intravitreal agents were effective in terms of visual results in the SRD patients; however, eyes treated with IVA and IVDI required fewer injections, as compared to the eyes treated with IVB and IVR. Furthermore, SRD entirely resolved in all eyes in the IVA group at the final follow-up visit.PMID:37408434 | DOI:10.1177/11206721231185909 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 6, 2023 Category: Opthalmology Authors: Bu ğra Karasu Enes Kesim Ali R ıza Cenk Celebi Source Type: research
Outcome of peripapillary polypoidal choroidal vasculopathy treatment using combination therapy intravitreal ranibizumab and thermal retinal laser photocoagulation
We present the case of a middle-aged female Nigerian diagnosed to have right eye peripapillary polypoidal choroidal vasculopathy (PCV). At presentation, her right eye Snellen visual acuity was 6/24+ (unaided) and 6/12 (aided) and the left eye was 6/9 (unaided) and 6/6 (aided). Fundus fluorescein angiography showed a hyperfluorescent peripapillary subretinal lesion associated with subretinal fluid demonstrated on spectral-domain optical coherence tomography. The PCV lesion was successfully treated using a combination of 3 monthly doses of intravitreal ranibizumab initially, followed by one session of focal therma...
Source: Annals of African Medicine - July 4, 2023 Category: African Health Authors: Ogugua Ndubuisi Okonkwo Toyin Akanbi Tolulope Odubela Martha-Mary Udoh Source Type: research
